Marksans Pharma Limited
MARKSANS · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹261.49.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%15.2%
- ✓Low debt (D/E < 0.5)0.11x
- ✓Positive free cash flow
- ✓Revenue growth > 10%21%
- ✓Earnings growing64%
- ✓Net margin ≥ 10%14.2%
- ✓Current ratio > 1.55.17
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.28
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 10.28.
Opportunities
- •Earnings growing (64% YoY).
- •Revenue growing (21% YoY).
- •Trading in our value buy zone versus sector peers.
- •Trades ~32% below our estimated fair value.
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, ant
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.